PubMed Health⌕ Search

Biomedical subjects

R E Gonsette

Publications and source records attributed to R E Gonsette.

12 recordsLinked to original sources
PubMed1978

Complement system activation by contrast media in neuroradiology.

Complement system activation was studied in six series of 12 patients undergoing routine contrast study following IV injection of five recently developed contrast media. The decreasing order of effectiveness on the complement system was as follows: ioxaglic acid, metrizamide, iodamidol. Metrizoic and ioxithalamic acids did not provoke any complement depletion at the doses used in this study. Both pathways of activating the complement system were involved. We could not find any definite correlation with osmolarity, ionic or nonionic formulation, protein binding, or hydrophobicity.

Complement Activation↗
PubMed1977

Potentiation of Amipaque epileptogenic activity by neuroleptics.

Experiments conducted on rabbits confirmed that chlorpromazine potentiates the weak epileptogenic action of Amipaque (metrizamide). Chlorpromazine withdrawal for a period of 48 h suppresses this potentiating effect in the rabbit. Neuroleptic drugs should therefore be avoided in patients examined with Amipaque. In patients under chronic treatment, neuroleptics ought to be discontinued at least 48 h before examination with Amipaque. With the doses and methods used in the present study, diazepam was not as effective as phenobarbital in preventing epilepsy produced by Amipaque. When premidication is needed or when convulsions occur after Amipaque examinations, combined diazepam and phenobarbital therapy ought to be instituted in order to achieve the best control of epileptic reactions.

Animals↗
PubMed1977

Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.

140 MS patients were treated with intensive I.V. cyclophosphamide immunotherapy and 110 were followed over 2-4 years. Annual relapse rate incidence was calculated over a period of 2 years before and after treatment and repeated neurological scores were made during this period. The conclusions are that 62% of the patients were stabilized during 2-4 years and that clinical improvement of the neurological signs was observed in most of the cases. It is concluded that intensive immunosuppression is able to interfere with the pathological processes involved in the pathogenesis of disseminated sclerosis.

Adult↗
PubMed1977

Cervical myelography with metrizamide by suboccipital puncture.

Cervical myelography with metrizamide (Amipaque) by suboccipital puncture was performed in 125 patients. Side effects were insignificant and there was no discomfort for the patient. The maximum amount to be injected is 3.75 g metrizamide (1.5 g iodine), and care must be taken in order to keep the contrast medium out of the basal cisterns. No premedication was used and no signs of irritation of the central nervous system were observed. With this technique the spinal cord and the nerve-roots are well demonstrated.

Humans↗
PubMed1977

Ventriculography with metrizamide.

Ventriculography with metrizamide (Amipaque) was performed in 150 patients. Side effects were mild and no severe reactions were observed. The low toxicity and the low epileptogenic activity of this contrast medium make positive contrast ventriculography a safe neuroradiologic procedure.

Cerebral Ventriculography↗
PubMed1976

Cervical myelography with a new resorbable contrast medium: Amipaque.

Cervical myelography with Amipaque was carried out on 1000 patients using the suboccipital puncture. The quality of the films is excellent and provides detailed informations on the spinal cord pathology and the cervical rootlets as well. Side effects are trivial and no case of epilepsy was observed in our group of patients.

Contrast Media↗
PubMedDate not supplied

[Clinical study of sodium dantroline (Dantrium) in multiple sclerosis (author's transl)].

The authors have studied the antispastic action of Dantrium in 50 patients with multiple sclerosis; in all cases, hypertonia, spasms or clonus constituted a severe obstacle to remedial therapy or nursing. After one year, the authors have found that Dantrium is effective in reducing hypertonia in 40% of the patients, in improving spasms in 65% and in reducing clonus in 50% of the cases. Secondary effects are fairly frequent (60%), characterized in most cases by diminished muscular strength and greater fatigability.

Clinical Trials as Topic↗